Prof. D'ACQUISTO Fulvio
Prof. D'ACQUISTO Fulvio

Email: fdacquisto@unite.it

Telefono: -

Dipartimento di appartenenza: BIOSCIENZE E TECNOLOGIE AGRO-ALIMENTARI E AMBIENTALI

 
 
 

Curriculum accademico

Professore Ordinario di Farmacologia, Università degli Studi di Teramo

Dipartimento di Bioscienze e Tecnologie Agro-Alimentari e Ambientali Università degli Studi di Teramo, Via Renato Balzarini 1, 64100 Teramo

  • Incarico onorario: Professore di Immunofarmacologia, William Harvey Research Institute, Queen Mary University of London (QMUL) — f.dacquisto@qmul.ac.uk
  • Adjunct Faculty, OSU Center for Health Sciences / OSU College of Osteopathic Medicine, Oklahoma State University (dal 2025)
  • Fondatore, Affective Immunology Research Program — il quadro traslazionale da me istituito che lega stati emotivi/psicosociali, stile di vita e risposta immunitaria, incentrato sulla scoperta e sullo sviluppo di terapie mirate all'Immuno-moodulina (Imood) per il trattamento di condizioni psichiatriche

Email: fdacquisto@unite.it ORCID: 0000-0002-4513-1608 Scopus Author ID: 6701351362

CARRIERA ACCADEMICA E PROFESSIONALE

  • 2020 – oggi: Titolare del modulo di Immunologia, II anno Medicina, Università Campus Bio-Medico di Roma
  • 2018 – 2022: Direttore, Health Science Centre e Professore di Immunologia e Immunofarmacologia, University of Roehampton
  • 2017 – 2025: Professore di Immunologia, School of Life and Health Science, University of Roehampton
  • 2014 – 2017: Co-Direttore, Biochemical Pharmacology, William Harvey Research Institute, QMUL
  • 2014 – 2017: Professore di Immunologia e Immunofarmacologia, QMUL
  • 2014 – 2016: Responsabile Ricerca Biomedica, Life Science Institute, QMUL
  • 2009 – 2014: Reader in Immunofarmacologia, QMUL
  • 2004 – 2009: Senior Lecturer in Immunofarmacologia, QMUL
  • 1999 – 2003: Postdoctoral Research Associate, Immunobiology, Yale University, USA (borsa Howard Hughes Medical Institute)
  • 1998: Visiting Scientist, Investigative Treatment Division, National Cancer Center Research Institute East, Kashiwa, Giappone
  • 1994: Visiting Researcher, Department of Gastroenterology, University of Calgary, Canada

FORMAZIONE

  • Dottorato di Ricerca in Farmacologia Sperimentale, Università degli Studi di Napoli "Federico II" (1996–1999; conseguito il 13 gennaio 2000)
  • Master in Farmacologia Sperimentale, Università degli Studi di Napoli "Federico II" (1994–1996)
  • Laurea in Chimica e Tecnologia Farmaceutiche, Università degli Studi di Napoli "Federico II" (1988–1994)
  • MA in Transpersonal Counselling and Psychotherapy, University of Northampton (2015–2017)
  • Diploma in Counselling & Psychotherapy, Centre for Counselling & Psychotherapy Education (CCPE) (2011–2014)
  • Psicoterapeuta iscritto BACP

ATTIVITÀ DI RICERCA

La mia attività di ricerca si concentra sull'immunologia affettiva — il rapporto bidirezionale tra stati emotivi/psicosociali e funzione immunitaria. In oltre 25 anni di ricerca traslazionale su infiammazione, autoimmunità e psiconeuroimmunologia, ho lavorato sia sull'immunità innata sia su quella adattativa, con particolare attenzione al sistema annessina A1/recettore per i peptidi formilati e, più recentemente, all'Immuno-moodulina (Imood/TDRP), un fattore di derivazione T-linfocitaria da me scoperto che collega l'attivazione immunitaria a comportamenti ansiosi e alterazioni del tono dell'umore. Sono unico inventore del brevetto statunitense US12,466,876 B2 (anticorpi anti-TDRP, concesso nel novembre 2025; titolare QMUL), e ho guidato attività traslazionali e di trasferimento tecnologico su questo target in collaborazione con partner biotecnologici.

La mia attività è stata sostenuta da oltre £2 milioni di finanziamenti alla ricerca nel Regno Unito (MRC, British Heart Foundation, Arthritis Research UK, Multiple Sclerosis Society, oltre a consulenze industriali), e sono autore o co-autore di oltre 100 pubblicazioni peer-reviewed, più del 60% come primo o ultimo autore.

FINANZIAMENTI ALLA RICERCA

  • "A novel facet in annexin-1 biology: modulation of the adaptive immune response" — MRC New Investigator Award, dic 2004–nov 2007. £250.000
  • "Modulation of T cell activation and differentiation by annexin-1" — Arthritis Research Campaign PhD studentship, ott 2005–set 2008. £66.474
  • "Research on annexin 1 and the adaptive immune response" — William Harvey Research Foundation, apr 2005–mar 2007. £120.000
  • "Immunomodulatory role of endogenous annexin-1 in dendritic cells" — Barts and the London Charitable Foundation, mar 2007–feb 2009. £99.594
  • "The impact of annexin 1 cleavage on neutrophil behaviour during the host response" — British Heart Foundation, apr 2007–mar 2010. £225.692
  • "Study of modulation of Toll-like receptor signalling by endogenous Annexin-1" — Barts and the London Charitable Foundation, ott 2007–set 2010. £70.373
  • "Generation of humanized antibody against Annexin-1 as therapeutic target for the treatment of Rheumatoid Arthritis" — Heptagon funding, ott 2008–mar 2010. £75.000
  • "Exploiting T cell Annexin-1 as target for the treatment of multiple sclerosis" — Multiple Sclerosis Society Innovative Award, mar 2008–feb 2009. £25.000
  • "Targeting anti-inflammatory therapy to arthritic joints" — Arthritis Research Campaign, dic 2008–nov 2010. £197.330
  • "Explorative investigations on the effects of recently discovered cytokines in inflammation" — William Harvey Research Foundation, nov 2009–ott 2011. £49.868
  • "IL-17A as a novel haemostatic and procoagulant agent" — Queen Mary Innovation Proof of Concept Funding, 2011. £11.610
  • "From the bench to the pipeline: developing a novel therapy for autoimmune diseases" — QMUL Principal's PhD studentship, gen 2011–feb 2014. £45.000
  • "Investigation of the inflammatory role of Th17 cell-derived cytokines" — MRC PhD studentship, gen 2011–feb 2014
  • "Volunteering in Mental Health Care for People with Psychosis (VOLUME)" — mar 2013–feb 2018. £1.980.907
  • "The development and therapeutic uses of monoclonal antibodies to Annexin-1" — pilot study sponsorizzato da Medannex, feb 2011–gen 2014. £369.343
  • "Immunological control of emotional behavior" — MRC PhD studentship, ott 2014–ott 2016. £75.000
  • "Targeting emotional disorders and mental health through the immune system" — MRC and Queen Mary Innovation, mag 2015–giu 2016. £49.950
  • "Investigating the impact of emotional states on the inflammatory response in atherosclerosis" — British Heart Foundation PhD studentship, ott 2016–ott 2019. £92.000
  • "Anti-Immuno-moodulin antibodies: a new way to treat mood disorders by targeting the immune system" — Innovation Funds, 2016–2017. £9.622
  • "Inspiring Young Scientists CPD Course" — QMUL Centre for Public Engagement Large Award, 2016–2017. £20.350
  • "A new drug target for the combined treatment of inflammatory disorders and emotional wellbeing" — UCB–Centre for Inflammation Therapeutic Innovation (CiTI) PhD studentship, gen 2018–dic 2020. £64.220,75
  • "Screening and identification of novel immunomodulatory cannabinoids" — Oxford Cannabinoid Technologies research collaboration, gen 2018–dic 2020. £600.287
  • "Immuno-moodulin as a novel biomarker and therapeutic target for mental disorders" — QMUL Impact Fund (Early Stage Commercialisation; BioPharma), giu 2022–mar 2024. £49.576

ATTIVITÀ DIDATTICA (ultimi 10 anni)

  • 2020 – oggi: Titolare del modulo di Immunologia, II anno Medicina, Università Campus Bio-Medico di Roma
  • 2017 – 2025: Titolare del modulo di Immunologia, II anno Biomedical Sciences, University of Roehampton (corso progettato ex novo)
  • 2014 – 2017: Titolare del modulo di Farmacologia Clinica, III anno Biomedical Sciences, QMUL (corso progettato ex novo)
  • 2012 – 2016: Coordinatore (con Prof. Paul Chapple e Prof. Amrita Ahluwalia), MRes in In Vivo Pharmacology, QMUL (finanziato da BHF e MRC)
  • 2012 – oggi: Docente ospite presso istituzioni internazionali, tra cui University of Glasgow e Institut Cochin, Parigi
  • 2008 – 2017: Tutor PBL per studenti di medicina, QMUL

CONFERENZE E SEMINARI SU INVITO

  • 2017 (marzo): "The immunological side of emotions and feelings. What's s..t got to do with it?" — Interdisciplinary Microbiome Project Hilary Term Seminar Series, Keble College, University of Oxford
  • 2017 (giugno): "The emotional side of rheumatic inflammatory diseases: a new venue for treatment" — relatore su invito, EULAR 2017 Sponsored Satellite Symposium ("How do we manage rheumatoid arthritis – in 2037?"), Feria de Madrid
  • 2017 (ottobre): Relatore su invito, 38° Congresso Nazionale SIF (Società Italiana di Farmacologia), Palacongressi di Rimini
  • 2018 (giugno): Relatore su invito, Immunoinflammation Roundtable, 1st Meeting in Translational Pharmacology, Santiago de Compostela
  • 2018 (dicembre): "Engaging young minds" — relatore su invito, simposio di public engagement "Let's Get Engaged! Marrying Pharmacological Research to Impact", Pharmacology 2018, British Pharmacological Society, Queen Elizabeth II Conference Centre, Londra
  • 2019 (maggio): Relatore su invito, Biologic Therapies VIII Summit: The Intersection of Rheumatology and Allied Specialties, Cleveland Clinic Center for Continuing Education, Global Center for Health Innovation, Cleveland, Ohio
  • 2020 (ottobre): "Affective Immunology: a new field of research at the intersection of emotions and the immune response" — relatore su invito, 6th Dubai International Nutrition Congress (DINC), Dubai Health Authority, Rashid Medical Library Auditorium, Dubai Health Innovation Center
  • 2021 (novembre): "Identifying and reaching new audiences via the Journal Frontiers for Young Minds" — RSB Connect 2021, simposio di outreach e public engagement della Royal Society of Biology
  • 2021 (ottobre): "Immuno-moodulin – an anxiogenic immune system protein" — relatore su invito, "Inflammation and Neuropsychiatric Disorders: Moving Forward", IRCCS Istituto Giannina Gaslini, Genova (con Associazione PANDAS Italia ODV)
  • 2022 (marzo): "The emotional side of autoimmune inflammatory disorders: a new venue for treatment?" — relatore su invito, Research Seminar Series, University of Surrey
  • 2022 (maggio–giugno): "Immuno-moodulin: a novel biomarker and therapeutic target for OCD and related disorders" — Simposio S14 ("Molecular pathways and circuitry mechanisms in Autism Spectrum Disorder and Obsessive Compulsive Disorder"), 8th Mediterranean Neuroscience Society (MNS) Conference, Dubrovnik, Croazia
  • 2022 (novembre): "Affective immunology: where emotions and immune response converge" — Eijkman Lecture (keynote di apertura), 20th Annual Infection & Immunity (I&I) Master's Symposium, Utrecht University, Paesi Bassi
  • 2023 (marzo): "The immunological side of emotions and feelings. What's s..t got to do with it?" — relatore su invito, British Veterinary Neurology Society (BVNS) Pre-BSAVA meeting ("Microbiome and the Brain"), Manchester Central Convention Complex
  • 2023 (ottobre): "The brain and autoimmunity: an introduction to 'mood immunology'" — The Twelfth Clinical Challenge in Rheumatology ("Ambiente e malattie reumatologiche"), Clinical and Experimental Rheumatology, Pisa
  • 2024 (settembre): Relatore su invito, Congresso International College of Obsessive Compulsive Spectrum Disorders (ICOCS), Milano
  • 2025 (giugno): "Immuno-modulin and neurodevelopmental disorders" — Faculty member, International Conference on Pediatric Acute-Onset Neuropsychiatric Syndrome: From Neuroinflammation to Clinical Practice, Università di Messina

SUPERVISIONE E MENTORING

Supervisione di 4 ricercatori postdoc, 8 dottorandi (fino al completamento), 3 studenti MRes MRC, 15 studenti MSc in Clinical Neuroscience, e oltre 50 studenti di medicina/scienze biomediche su progetti di ricerca; guida di oltre 30 studenti di medicina nei loro progetti SSC (Selected Student Component).

TRASFERIMENTO TECNOLOGICO E CONSULENZA INDUSTRIALE

  • Consulente di ricerca per aziende biotecnologiche e farmaceutiche tra cui Ziarco Pharma Ltd, Cerebos Pacific Ltd e Oxford Cannabinoid Technologies (oltre £400.000 in compensi di consulenza cumulativi)
  • L'attività di consulenza spazia dalla validazione di target immunitari e scoperta di biomarcatori, alla progettazione di ricerca traslazionale dal preclinico al clinico, alla strategia brevettuale e allo sviluppo di proprietà intellettuale in immunofarmacologia
  • Unico o co-inventore di diverse domande di brevetto derivanti da tale attività, con licenze a Medannex Ltd (medannex.org), Karla Therapeutics (karla-tx.com) e NLC Health (nlc.health)

ATTIVITÀ EDITORIALE

  • Associate Editor, Pharmacology & Therapeutics (dal 2017)
  • Associate Editor, Heliyon (dal 2018)
  • Chief Editor, Frontiers for Young Minds (dal 2016)
  • Associate Editor, Frontiers in Immunology (dal 2010)
  • Associate Editor, Frontiers in Pharmacology (dal 2019)
  • Associate Editor, Scientific Reports (dal 2014)
  • Associate Editor, PeerJ (dal 2014)
  • Associate Editor, PLOS ONE (dal 2014)
  • Associate Editor, Biochemical Pharmacology (dal 2008)
  • Associate Editor, Mediators of Inflammation (dal 2007)

ATTIVITÀ DI REVISIONE

  • Revisore per il Newton Fund
  • Revisore per il Ministero dell'Istruzione, dell'Università e della Ricerca, anche in qualità di presidente di commissione (due volte) e membro di commissione (oltre 6 anni) per programmi di valutazione della ricerca
  • Revisore per The Knowledge Foundation
  • Revisore per il Translational Research Evaluation Committee della French National Research Agency (ANR)
  • Revisore per la Romanian National Authority for Scientific Research and Innovation
  • Revisore per il Fund for Scientific Research (FNRS)
  • Revisore per il Research Grants scheme della Royal Society
  • Revisore per le MRC Clinical Research Training Fellowships

RICONOSCIMENTI

  • Fellow della Royal Society of Biology
  • Medical Research Council New Investigator Award
  • Personale valutato RAE (Research Assessment Exercise) 2008; personale valutato REF (Research Excellence Framework) 2014 e 2021
  • Frontiers Travel Award, 2015 (riconoscimento per il servizio editoriale come Review Editor di Frontiers in Immunology) — frontiersin.org

DIVULGAZIONE SCIENTIFICA

Curriculum english version

Full Professor of Pharmacology, University of Teramo

Department of Bioscience and Technology for Food, Agriculture and Environment University of Teramo, Via Renato Balzarini 1, 64100 Teramo, Italy

  • Honorary appointment: Professor of Immunopharmacology, William Harvey Research Institute, Queen Mary University of London (QMUL) — f.dacquisto@qmul.ac.uk
  • Adjunct Faculty, OSU Center for Health Sciences / OSU College of Osteopathic Medicine, Oklahoma State University (since 2025)
  • Founder, Affective Immunology Research Program — the translational framework I established linking emotional/psychosocial states, lifestyle and immune responses, anchored in the discovery and development of Immuno-moodulin (Imood)-targeted therapies for the treatment of psychiatric conditions

Email: fdacquisto@unite.it ORCID: 0000-0002-4513-1608 Scopus Author ID: 6701351362

ACADEMIC AND PROFESSIONAL ACTIVITY

  • 2020 – present: Module Leader, Immunology, Year 2 Medical Students, Campus Bio-Medico University of Rome
  • 2018 – 2022: Director, Health Science Centre & Professor of Immunology and Immunopharmacology, University of Roehampton
  • 2017 – 2025: Professor of Immunology, School of Life and Health Science, University of Roehampton
  • 2014 – 2017: Co-Director, Biochemical Pharmacology, William Harvey Research Institute, QMUL
  • 2014 – 2017: Professor in Immunology and Immunopharmacology, QMUL
  • 2014 – 2016: Biomedical Research Lead, Life Science Institute, QMUL
  • 2009 – 2014: Reader in Immunopharmacology, QMUL
  • 2004 – 2009: Senior Lecturer in Immunopharmacology, QMUL
  • 1999 – 2003: Postdoctoral Research Associate, Immunobiology, Yale University, USA (Howard Hughes Medical Institute-funded)
  • 1998: Visiting Scientist, Investigative Treatment Division, National Cancer Center Research Institute East, Kashiwa, Japan
  • 1994: Visiting Researcher, Department of Gastroenterology, University of Calgary, Canada

EDUCATION

  • PhD in Experimental Pharmacology, University of Naples "Federico II" (1996–1999; conferred 13 January 2000)
  • Master in Experimental Pharmacology, University of Naples "Federico II" (1994–1996)
  • Degree in Pharmaceutical Chemistry, University of Naples "Federico II" (1988–1994)
  • MA in Transpersonal Counselling and Psychotherapy, University of Northampton (2015–2017)
  • Diploma in Counselling & Psychotherapy, Centre for Counselling & Psychotherapy Education (CCPE) (2011–2014)
  • BACP-registered psychotherapist

RESEARCH ACTIVITY

My research programme centres on affective immunology — the bidirectional relationship between emotional and psychosocial states and immune function. Over more than 25 years of translational research in inflammation, autoimmunity and psychoneuroimmunology, I have worked across both innate and adaptive immunity, with a particular focus on the annexin A1/formyl peptide receptor system and, more recently, on Immuno-moodulin (Imood/TDRP), a T cell-derived factor I discovered linking immune activation to anxiety- and mood-related behaviour. I am the sole inventor of US Patent US12,466,876 B2 (TDRP antibodies, granted November 2025; QMUL as assignee), and have led translational and industry-facing work on this target through licensing to biotech partners.

My work has been supported by over £2 million in UK research funding (MRC, British Heart Foundation, Arthritis Research UK, Multiple Sclerosis Society, and industry consultancy), and I have authored or co-authored more than 100 peer-reviewed publications, over 60% as first or last author.

RESEARCH GRANTS

  • "A novel facet in annexin-1 biology: modulation of the adaptive immune response" — MRC New Investigator Award, Dec 2004–Nov 2007. £250,000
  • "Modulation of T cell activation and differentiation by annexin-1" — Arthritis Research Campaign PhD studentship, Oct 2005–Sep 2008. £66,474
  • "Research on annexin 1 and the adaptive immune response" — William Harvey Research Foundation, Apr 2005–Mar 2007. £120,000
  • "Immunomodulatory role of endogenous annexin-1 in dendritic cells" — Barts and the London Charitable Foundation, Mar 2007–Feb 2009. £99,594
  • "The impact of annexin 1 cleavage on neutrophil behaviour during the host response" — British Heart Foundation, Apr 2007–Mar 2010. £225,692
  • "Study of modulation of Toll-like receptor signalling by endogenous Annexin-1" — Barts and the London Charitable Foundation, Oct 2007–Sep 2010. £70,373
  • "Generation of humanized antibody against Annexin-1 as therapeutic target for the treatment of Rheumatoid Arthritis" — Heptagon funding, Oct 2008–Mar 2010. £75,000
  • "Exploiting T cell Annexin-1 as target for the treatment of multiple sclerosis" — Multiple Sclerosis Society Innovative Award, Mar 2008–Feb 2009. £25,000
  • "Targeting anti-inflammatory therapy to arthritic joints" — Arthritis Research Campaign, Dec 2008–Nov 2010. £197,330
  • "Explorative investigations on the effects of recently discovered cytokines in inflammation" — William Harvey Research Foundation, Nov 2009–Oct 2011. £49,868
  • "IL-17A as a novel haemostatic and procoagulant agent" — Queen Mary Innovation Proof of Concept Funding, 2011. £11,610
  • "From the bench to the pipeline: developing a novel therapy for autoimmune diseases" — QMUL Principal's PhD studentship, Jan 2011–Feb 2014. £45,000
  • "Investigation of the inflammatory role of Th17 cell-derived cytokines" — MRC PhD studentship, Jan 2011–Feb 2014
  • "Volunteering in Mental Health Care for People with Psychosis (VOLUME)" — Mar 2013–Feb 2018. £1,980,907
  • "The development and therapeutic uses of monoclonal antibodies to Annexin-1" — pilot study sponsored by Medannex, Feb 2011–Jan 2014. £369,343
  • "Immunological control of emotional behavior" — MRC PhD studentship, Oct 2014–Oct 2016. £75,000
  • "Targeting emotional disorders and mental health through the immune system" — MRC and Queen Mary Innovation, May 2015–Jun 2016. £49,950
  • "Investigating the impact of emotional states on the inflammatory response in atherosclerosis" — British Heart Foundation PhD studentship, Oct 2016–Oct 2019. £92,000
  • "Anti-Immuno-moodulin antibodies: a new way to treat mood disorders by targeting the immune system" — Innovation Funds, 2016–2017. £9,622
  • "Inspiring Young Scientists CPD Course" — QMUL Centre for Public Engagement Large Award, 2016–2017. £20,350
  • "A new drug target for the combined treatment of inflammatory disorders and emotional wellbeing" — UCB–Centre for Inflammation Therapeutic Innovation (CiTI) PhD studentship, Jan 2018–Dec 2020. £64,220.75
  • "Screening and identification of novel immunomodulatory cannabinoids" — Oxford Cannabinoid Technologies research collaboration, Jan 2018–Dec 2020. £600,287
  • "Immuno-moodulin as a novel biomarker and therapeutic target for mental disorders" — QMUL Impact Fund (Early Stage Commercialisation; BioPharma), Jun 2022–Mar 2024. £49,576

TEACHING ACTIVITY (last 10 years)

  • 2020 – present: Module leader, Immunology, Year 2 Medical Students, Campus Bio-Medico University of Rome
  • 2017 – 2025: Module leader, Immunology, Year 2 Biomedical Students, University of Roehampton (course designed from scratch)
  • 2014 – 2017: Module leader, Clinical Pharmacology, Year 3 Biomedical Students, QMUL (course designed from scratch)
  • 2012 – 2016: Course leader (with Prof. Paul Chapple and Prof. Amrita Ahluwalia), MRes in In Vivo Pharmacology, QMUL (BHF- and MRC-funded)
  • 2012 – present: Invited lecturer at international institutions including the University of Glasgow and the Institut Cochin, Paris
  • 2008 – 2017: PBL tutor for medical students, QMUL

INVITED TALKS & SEMINARS

  • 2017 (March): "The immunological side of emotions and feelings. What's s..t got to do with it?" — Interdisciplinary Microbiome Project Hilary Term Seminar Series, Keble College, University of Oxford
  • 2017 (June): "The emotional side of rheumatic inflammatory diseases: a new venue for treatment" — invited speaker, EULAR 2017 Sponsored Satellite Symposium ("How do we manage rheumatoid arthritis – in 2037?"), Feria de Madrid
  • 2017 (October): Invited speaker, 38° Congresso Nazionale SIF (Società Italiana di Farmacologia), Palacongressi di Rimini
  • 2018 (June): Invited speaker, Immunoinflammation Roundtable, 1st Meeting in Translational Pharmacology, Santiago de Compostela
  • 2018 (December): "Engaging young minds" — invited speaker, public engagement symposium "Let's Get Engaged! Marrying Pharmacological Research to Impact", Pharmacology 2018, British Pharmacological Society, Queen Elizabeth II Conference Centre, London
  • 2019 (May): Invited speaker, Biologic Therapies VIII Summit: The Intersection of Rheumatology and Allied Specialties, Cleveland Clinic Center for Continuing Education, Global Center for Health Innovation, Cleveland, Ohio
  • 2020 (October): "Affective Immunology: a new field of research at the intersection of emotions and the immune response" — invited speaker, 6th Dubai International Nutrition Congress (DINC), Dubai Health Authority, Rashid Medical Library Auditorium, Dubai Health Innovation Center
  • 2021 (November): "Identifying and reaching new audiences via the Journal Frontiers for Young Minds" — RSB Connect 2021, Royal Society of Biology outreach and engagement symposium
  • 2021 (October): "Immuno-moodulin – an anxiogenic immune system protein" — invited speaker, "Inflammation and Neuropsychiatric Disorders: Moving Forward", IRCCS Istituto Giannina Gaslini, Genoa (with Associazione PANDAS Italia ODV)
  • 2022 (March): "The emotional side of autoimmune inflammatory disorders: a new venue for treatment?" — invited speaker, Research Seminar Series, University of Surrey
  • 2022 (May–June): "Immuno-moodulin: a novel biomarker and therapeutic target for OCD and related disorders" — Symposium S14 ("Molecular pathways and circuitry mechanisms in Autism Spectrum Disorder and Obsessive Compulsive Disorder"), 8th Mediterranean Neuroscience Society (MNS) Conference, Dubrovnik, Croatia
  • 2022 (November): "Affective immunology: where emotions and immune response converge" — Eijkman Lecture (opening keynote), 20th Annual Infection & Immunity (I&I) Master's Symposium, Utrecht University, Netherlands
  • 2023 (March): "The immunological side of emotions and feelings. What's s..t got to do with it?" — invited speaker, British Veterinary Neurology Society (BVNS) Pre-BSAVA meeting ("Microbiome and the Brain"), Manchester Central Convention Complex
  • 2023 (October): "The brain and autoimmunity: an introduction to 'mood immunology'" — The Twelfth Clinical Challenge in Rheumatology ("Ambiente e malattie reumatologiche"), Clinical and Experimental Rheumatology, Pisa
  • 2024 (September): Invited speaker, International College of Obsessive Compulsive Spectrum Disorders (ICOCS) Congress, Milan
  • 2025 (June): "Immuno-modulin and neurodevelopmental disorders" — Faculty member, International Conference on Pediatric Acute-Onset Neuropsychiatric Syndrome: From Neuroinflammation to Clinical Practice, University of Messina

SUPERVISION AND MENTORING

Supervised 4 postdoctoral researchers, 8 PhD students to completion, 3 MRC MRes students, 15 MSc students in Clinical Neuroscience, and more than 50 medical or biomedical students on practical research projects; guided more than 30 medical students through their Selected Student Component (SSC) projects.

TECHNOLOGY TRANSFER AND INDUSTRY CONSULTANCY

  • Contract research consultant for biotechnology and pharmaceutical companies including Ziarco Pharma Ltd, Cerebos Pacific Ltd and Oxford Cannabinoid Technologies (over £400,000 in cumulative consultancy fees)
  • Consultancy expertise spans immune target validation and biomarker discovery, translational research design bridging preclinical to clinical phases, and patent strategy and IP development in immunopharmacology
  • Sole or co-inventor on patent applications arising from this work, with licenses to Medannex Ltd (medannex.org), Karla Therapeutics (karla-tx.com) and NLC Health (nlc.health)

EDITORIAL ACTIVITY

  • Associate Editor, Pharmacology & Therapeutics (since 2017)
  • Associate Editor, Heliyon (since 2018)
  • Chief Editor, Frontiers for Young Minds (since 2016)
  • Associate Editor, Frontiers in Immunology (since 2010)
  • Associate Editor, Frontiers in Pharmacology (since 2019)
  • Associate Editor, Scientific Reports (since 2014)
  • Associate Editor, PeerJ (since 2014)
  • Associate Editor, PLOS ONE (since 2014)
  • Associate Editor, Biochemical Pharmacology (since 2008)
  • Associate Editor, Mediators of Inflammation (since 2007)

REVIEWING ACTIVITY

  • Reviewer for the Newton Fund
  • Reviewer for the Italian Ministry of Education, University and Research, including as panel chair (twice) and panel member (more than 6 years) for research funding evaluation schemes
  • Reviewer for The Knowledge Foundation
  • Reviewer for the Translational Research Evaluation Committee of the French National Research Agency (ANR)
  • Reviewer for the Romanian National Authority for Scientific Research and Innovation
  • Reviewer for the Fund for Scientific Research (FNRS)
  • Reviewer for the Royal Society Research Grants scheme
  • Reviewer for MRC Clinical Research Training Fellowships

AWARDS

  • Fellow of the Royal Society of Biology
  • Medical Research Council New Investigator Award
  • Research Assessment Exercise (RAE)-returned staff, 2008; Research Excellence Framework (REF)-returned staff, 2014 and 2021
  • Frontiers Travel Award, 2015 (recognizing outstanding editorial service as Review Editor of Frontiers in Immunology) — frontiersin.org

PUBLIC ENGAGEMENT

Pubblicazioni

Full Publication list1-105

 

  1. Ju C, Ogura A, Hayashi Y, Kawabata Y, D'Acquisto F, Kawakubo-Yasukochi T, Jimi E. The impact of environmental enrichment on energy metabolism in ovariectomized mice. PLoS One. 2025 Apr 2;20(4):e0320180. doi: 10.1371/journal.pone.0320180. PMID: 40173406
  2. Loiodice S, D'Acquisto F, Drinkenburg P, Suojanen C, Llorca PM, Manji HK. Neuropsychiatric drug development: Perspectives on the current landscape, opportunities and potential future directions.
  3. Drug Discov Today. 2025 Jan;30(1):104255. doi: 10.1016/j.drudis.2024.104255. Epub 2024 Nov 29.
  4. PMID: 39615745

 

  1. Sabatucci A, Girella A, Di Bartolomeo M, Pucci M, Vismara M, Benatti B, Blacksell IA, Cooper D, Dainese E, D'Acquisto F, Dell'Osso B, D'Addario C: A possible role for G-quadruplexes formation and DNA methylation at IMOOD gene promoter in Obsessive Compulsive Disorder. Adv Biol Regul 2023, 89:100976.
  2. Sabatucci A, Girella A, Di Bartolomeo M, Pucci M, Vismara M, Benatti B, Blacksell IA, Cooper D, Dainese E, D'Acquisto F, Dell'Osso B, D'Addario C: A possible role for G-quadruplexes formation and DNA methylation at IMOOD gene promoter in Obsessive Compulsive Disorder. Adv Biol Regul 2023, 89:100976.
  3. Boolani A, Martin J, D'Acquisto F, Balestra C: Editorial: Feelings of energy and fatigue: Two different moods. Front Psychol 2023, 14:1180285.
  4. D'Acquisto F, D'Addario C, Cooper D, Pallanti S, Blacksell I: Peripheral control of psychiatric disorders: Focus on OCD. Are we there yet? Compr Psychiatry 2023, 123:152388.
  5. Rathod KS, Kapil V, Velmurugan S, Khambata RS, Siddique U, Khan S, Van Eijl S, Gee LC, Bansal J, Pitrola K, Shaw C, D'Acquisto F, Colas RA, Marelli-Berg F, Dalli J, Ahluwalia A: Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J Clin Invest 2023, 133.
  6. D'Acquisto F: The microbiome, IgGs and schizophrenia. A R20+ adult-only story. Brain Behav Immun 2023, 107:397-8.
  7. Hamilton A, Rizzo R, Brod S, Ono M, Perretti M, Cooper D, D'Acquisto F: The immunomodulatory effects of social isolation in mice are linked to temperature control. Brain Behav Immun 2022, 102:179-94.
  8. Gentile A, D'Acquisto F, Leposavic G: Editorial: The Bidirectional Communication Between Neurons and Immune Cells in the Development of Psychiatric, Neurological and Immune-Mediated Disorders. Front Immunol 2021, 12:781151.
  9. D'Acquisto F, Hamilton A: Cardiovascular and immunological implications of social distancing in the context of COVID-19. Cardiovasc Res 2020, 116:e129-e31.
  10. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F, Nicklin SA, Marian AJ, Nosalski R, Murray EC, Guzik B, Berry C, Touyz RM, Kreutz R, Wang DW, Bhella D, Sagliocco O, Crea F, Thomson EC, McInnes IB: COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020, 116:1666-87.
  11. Piras G, Rattazzi L, Paschalidis N, Oggero S, Berti G, Ono M, Bellia F, D'Addario C, Dell'Osso B, Pariante CM, Perretti M, D'Acquisto F: Immuno-moodulin: A new anxiogenic factor produced by Annexin-A1 transgenic autoimmune-prone T cells. Brain Behav Immun 2020, 87:689-702.
  12. Podaru MN, Fields L, Kainuma S, Ichihara Y, Hussain M, Ito T, Kobayashi K, Mathur A, D'Acquisto F, Lewis-McDougall F, Suzuki K: Reparative macrophage transplantation for myocardial repair: a refinement of bone marrow mononuclear cell-based therapy. Basic Res Cardiol 2019, 114:34.
  13. Maione F, Iqbal AJ, Raucci F, Letek M, Bauer M, D'Acquisto F: Repetitive Exposure of IL-17 Into the Murine Air Pouch Favors the Recruitment of Inflammatory Monocytes and the Release of IL-16 and TREM-1 in the Inflammatory Fluids. Front Immunol 2018, 9:2752.
  14. Yanez DC, Sahni H, Ross S, Solanki A, Lau CI, Papaioannou E, Barbarulo A, Powell R, Lange UC, Adams DJ, Barenco M, Ono M, D'Acquisto F, Furmanski AL, Crompton T: IFITM proteins drive type 2 T helper cell differentiation and exacerbate allergic airway inflammation. Eur J Immunol 2019, 49:66-78.
  15. Hernandez-Ramirez LC, Morgan RML, Barry S, D'Acquisto F, Prodromou C, Korbonits M: Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland. Oncotarget 2018, 9:9177-98.
  16. D'Acquisto F: Affective immunology: where emotions and the immune response converge. Dialogues Clin Neurosci 2017, 19:9-19.
  17. Ghezzi P, Floridi L, Boraschi D, Cuadrado A, Manda G, Levic S, D'Acquisto F, Hamilton A, Athersuch TJ, Selley L: Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. Antioxid Redox Signal 2018, 28:852-72.
  18. Brod S, Gobbetti T, Gittens B, Ono M, Perretti M, D'Acquisto F: The impact of environmental enrichment on the murine inflammatory immune response. JCI Insight 2017, 2:e90723.
  19. Rathod KS, Kapil V, Velmurugan S, Khambata RS, Siddique U, Khan S, Van Eijl S, Gee LC, Bansal J, Pitrola K, Shaw C, D'Acquisto F, Colas RA, Marelli-Berg F, Dalli J, Ahluwalia A: Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J Clin Invest 2017, 127:169-82.
  20. Rattazzi L, Piras G, Brod S, Smith K, Ono M, D'Acquisto F: Impact of Enriched Environment on Murine T Cell Differentiation and Gene Expression Profile. Front Immunol 2016, 7:381.
  21. D'Acquisto F: Editorial overview: Immunomodulation: Exploiting the circle between emotions and immunity: impact on pharmacological treatments. Curr Opin Pharmacol 2016, 29:viii-xii.
  22. Hernandez-Ramirez LC, Martucci F, Morgan RM, Trivellin G, Tilley D, Ramos-Guajardo N, Iacovazzo D, D'Acquisto F, Prodromou C, Korbonits M: Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations. J Clin Endocrinol Metab 2016, 101:3144-54.
  23. Vagaska B, New SE, Alvarez-Gonzalez C, D'Acquisto F, Gomez SG, Bulstrode NW, Madrigal A, Ferretti P: MHC-class-II are expressed in a subpopulation of human neural stem cells in vitro in an IFNgamma-independent fashion and during development. Sci Rep 2016, 6:24251.
  24. Rattazzi L, Cariboni A, Poojara R, Shoenfeld Y, D'Acquisto F: Impaired sense of smell and altered olfactory system in RAG-1(-∕-) immunodeficient mice. Front Neurosci 2015, 9:318.
  25. Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D'Acquisto F, Bland EJ, Bombardieri M, Pitzalis C, Perretti M, Marelli-Berg FM, Mauro C: Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. PLoS Biol 2015, 13:e1002202.
  26. Major B, Rattazzi L, Brod S, Pilipovic I, Leposavic G, D'Acquisto F: Massage-like stroking boosts the immune system in mice. Sci Rep 2015, 5:10913.
  27. Furmanski AL, Barbarulo A, Solanki A, Lau CI, Sahni H, Saldana JI, D'Acquisto F, Crompton T: The transcriptional activator Gli2 modulates T-cell receptor signalling through attenuation of AP-1 and NFkappaB activity. J Cell Sci 2015, 128:2085-95.
  28. Gallo I, Rattazzi L, Piras G, Gobbetti T, Panza E, Perretti M, Dalley JW, D'Acquisto F: Formyl peptide receptor as a novel therapeutic target for anxiety-related disorders. PLoS One 2014, 9:e114626.
  29. Allegra M, D'Acquisto F, Tesoriere L, Attanzio A, Livrea MA: Pro-oxidant activity of indicaxanthin from Opuntia ficus indica modulates arachidonate metabolism and prostaglandin synthesis through lipid peroxide production in LPS-stimulated RAW 264.7 macrophages. Redox Biol 2014, 2:892-900.
  30. D'Acquisto F, Rattazzi L, Piras G: Smile--It's in your blood! Biochem Pharmacol 2014, 91:287-92.
  31. Hughes C, Sette A, Seed M, D'Acquisto F, Manzo A, Vincent TL, Lim NH, Nissim A: Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency. Arthritis Res Ther 2014, 16:R151.
  32. D'Acquisto F, Rattazzi L, Piras G, Galuppo ML: Novel immunological targets in rheumatic diseases: clues from current therapies. Drug Discov Today 2014, 19:1155-60.
  33. Brod S, Rattazzi L, Piras G, D'Acquisto F: 'As above, so below' examining the interplay between emotion and the immune system. Immunology 2014, 143:311-8.
  34. Maione F, Parisi A, Caiazzo E, Morello S, D'Acquisto F, Mascolo N, Cicala C: Interleukin-17A Exacerbates Ferric Chloride-Induced Arterial Thrombosis in Rat Carotid Artery. Int J Inflam 2014, 2014:247503.
  35. Piras G, Rattazzi L, McDermott A, Deacon R, D'Acquisto F: Emotional change-associated T cell mobilization at the early stage of a mouse model of multiple sclerosis. Front Immunol 2013, 4:400.
  36. Rattazzi L, Piras G, Ono M, Deacon R, Pariante CM, D'Acquisto F: CD4(+) but not CD8(+) T cells revert the impaired emotional behavior of immunocompromised RAG-1-deficient mice. Transl Psychiatry 2013, 3:e280.
  37. Sampaio AL, Dalli J, Brancaleone V, D'Acquisto F, Perretti M, Wheatley C: Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression. Mediators Inflamm 2013, 2013:741804.
  38. Shintani Y, Kapoor A, Kaneko M, Smolenski RT, D'Acquisto F, Coppen SR, Harada-Shoji N, Lee HJ, Thiemermann C, Takashima S, Yashiro K, Suzuki K: TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proc Natl Acad Sci U S A 2013, 110:5109-14.
  39. D'Acquisto F, Piras G, Rattazzi L: Pro-inflammatory and pathogenic properties of Annexin-A1: the whole is greater than the sum of its parts. Biochem Pharmacol 2013, 85:1213-8.
  40. Furmanski AL, Saldana JI, Ono M, Sahni H, Paschalidis N, D'Acquisto F, Crompton T: Tissue-derived hedgehog proteins modulate Th differentiation and disease. J Immunol 2013, 190:2641-9.
  41. Proebstl D, Voisin MB, Woodfin A, Whiteford J, D'Acquisto F, Jones GE, Rowe D, Nourshargh S: Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J Exp Med 2012, 209:1219-34.
  42. Patel HB, Kornerup KN, Sampaio AL, D'Acquisto F, Seed MP, Girol AP, Gray M, Pitzalis C, Oliani SM, Perretti M: The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann Rheum Dis 2012, 71:1872-80.
  43. Kabouridis PS, Pimentel TA, Brancaleone V, D'Acquisto F, Oliani SM, Perretti M, Jury EC: Distinct localization of T cell Agrin during antigen presentation--evidence for the expression of Agrin receptor(s) in antigen-presenting cells. FEBS J 2012, 279:2368-80.
  44. D'Acquisto F, Crompton T: CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response? Biochem Pharmacol 2011, 82:333-40.
  45. Maione F, Cicala C, Liverani E, Mascolo N, Perretti M, D'Acquisto F: IL-17A increases ADP-induced platelet aggregation. Biochem Biophys Res Commun 2011, 408:658-62.
  46. Leger T, Grist J, D'Acquisto F, Clark AK, Malcangio M: Glatiramer acetate attenuates neuropathic allodynia through modulation of adaptive immune cells. J Neuroimmunol 2011, 234:19-26.
  47. Allegra M, D'Acquisto F, Tesoriere L, Livrea MA, Perretti M: Cross-talk between minimally primed HL-60 cells and resting HUVEC reveals a crucial role for adhesion over extracellularly released oxidants. Biochem Pharmacol 2011, 81:396-401.
  48. Spurr L, Nadkarni S, Pederzoli-Ribeil M, Goulding NJ, Perretti M, D'Acquisto F: Comparative analysis of Annexin A1-formyl peptide receptor 2/ALX expression in human leukocyte subsets. Int Immunopharmacol 2011, 11:55-66.
  49. Renshaw D, Montero-Melendez T, Dalli J, Kamal A, Brancaleone V, D'Acquisto F, Cirino G, Perretti M: Downstream gene activation of the receptor ALX by the agonist annexin A1. PLoS One 2010, 5.
  50. Pimentel TA, Sampaio AL, D'Acquisto F, Perretti M, Oliani SM: An essential role for mast cells as modulators of neutrophils influx in collagen-induced arthritis in the mouse. Lab Invest 2011, 91:33-42.
  51. Pederzoli-Ribeil M, Maione F, Cooper D, Al-Kashi A, Dalli J, Perretti M, D'Acquisto F: Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature. Blood 2010, 116:4288-96.
  52. Patel HB, Bombardieri M, Sampaio AL, D'Acquisto F, Gray M, Grieco P, Getting SJ, Pitzalis C, Perretti M: Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB J 2010, 24:4835-43.
  53. Staniland AA, Clark AK, Wodarski R, Sasso O, Maione F, D'Acquisto F, Malcangio M: Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 2010, 114:1143-57.
  54. Maione F, Paschalidis N, Iqbal AJ, Crompton T, Perretti M, D'Acquisto F: Analysis of the inflammatory response in HY-TCR transgenic mice highlights the pathogenic potential of CD4- CD8- T cells. Autoimmunity 2010, 43:672-81.
  55. Souslova V, Townsend PA, Mann J, van der Loos CM, Motterle A, D'Acquisto F, Mann DA, Ye S: Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFkappaB. PLoS One 2010, 5:e9902.
  56. Paschalidis N, Huggins A, Rowbotham NJ, Furmanski AL, Crompton T, Flower RJ, Perretti M, D'Acquisto F: Role of endogenous annexin-A1 in the regulation of thymocyte positive and negative selection. Cell Cycle 2010, 9:784-93.
  57. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D'Acquisto F, Buckingham JC, Perretti M, Flower RJ: Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010, 184:2611-9.
  58. Paschalidis N, Iqbal AJ, Maione F, Wood EG, Perretti M, Flower RJ, D'Acquisto F: Modulation of experimental autoimmune encephalomyelitis by endogenous annexin A1. J Neuroinflammation 2009, 6:33.
  59. D'Acquisto F, Maione F, Pederzoli-Ribeil M: From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead? Biochem Pharmacol 2010, 79:525-34.
  60. D'Acquisto F: On the adaptive nature of annexin-A1. Curr Opin Pharmacol 2009, 9:521-8.
  61. Ianaro A, Tersigni M, D'Acquisto F: New insight in LPS antagonist. Mini Rev Med Chem 2009, 9:306-17.
  62. Perretti M, D'Acquisto F: Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009, 9:62-70.
  63. Maione F, Paschalidis N, Mascolo N, Dufton N, Perretti M, D'Acquisto F: Interleukin 17 sustains rather than induces inflammation. Biochem Pharmacol 2009, 77:878-87.
  64. Huggins A, Paschalidis N, Flower RJ, Perretti M, D'Acquisto F: Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation. FASEB J 2009, 23:985-96.
  65. Matthews L, Berry A, Tersigni M, D'Acquisto F, Ianaro A, Ray D: Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology 2009, 150:75-86.
  66. D'Acquisto F, Perretti M, Flower RJ: Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. Br J Pharmacol 2008, 155:152-69.
  67. D'Acquisto F, Paschalidis N, Raza K, Buckley CD, Flower RJ, Perretti M: Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells. Rheumatology (Oxford) 2008, 47:636-9.
  68. Taher TE, Tulone C, Fatah R, D'Acquisto F, Gould DJ, Mageed RA: Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors. Gene Ther 2008, 15:998-1006.
  69. D'Acquisto F, Paschalidis N, Sampaio AL, Merghani A, Flower RJ, Perretti M: Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur J Immunol 2007, 37:3131-42.
  70. Vong L, D'Acquisto F, Pederzoli-Ribeil M, Lavagno L, Flower RJ, Witko-Sarsat V, Perretti M: Annexin 1 cleavage in activated neutrophils: a pivotal role for proteinase 3. J Biol Chem 2007, 282:29998-30004.
  71. D'Acquisto F, Merghani A, Lecona E, Rosignoli G, Raza K, Buckley CD, Flower RJ, Perretti M: Annexin-1 modulates T-cell activation and differentiation. Blood 2007, 109:1095-102.
  72. Clark AK, D'Aquisto F, Gentry C, Marchand F, McMahon SB, Malcangio M: Rapid co-release of interleukin 1beta and caspase 1 in spinal cord inflammation. J Neurochem 2006, 99:868-80.
  73. D'Acquisto F, Ianaro A: From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors. Curr Opin Pharmacol 2006, 6:387-92.
  74. Perretti M, D'Acquisto F: Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Inflamm Allergy Drug Targets 2006, 5:107-14.
  75. Damazo AS, Yona S, D'Acquisto F, Flower RJ, Oliani SM, Perretti M: Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation. Am J Pathol 2005, 166:1607-17.
  76. Lee KY, D'Acquisto F, Hayden MS, Shim JH, Ghosh S: PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 2005, 308:114-8.
  77. Ialenti A, Di Meglio P, D'Acquisto F, Pisano B, Maffia P, Grassia G, Di Rosa M, Ianaro A: Inhibition of cyclooxygenase-2 gene expression by the heat shock response in J774 murine macrophages. Eur J Pharmacol 2005, 509:89-96.
  78. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S: Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004, 10:617-24.
  79. D'Acquisto F, May MJ, Ghosh S: Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv 2002, 2:22-35.
  80. Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N, Nghiem M, Griffiths EK, Krawczyk C, Bauer B, D'Acquisto F, Ghosh S, Yeh WC, Baier G, Rottapel R, Penninger JM: The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003, 18:763-75.
  81. D'Acquisto F, Ghosh S: PACT and PKR: turning on NF-kappa B in the absence of virus. Sci STKE 2001, 2001:re1.
  82. D'Acquisto F, Ianaro A, Ialenti A, Maffia P, Maiuri MC, Carnuccio R: Transcription factor decoy oligodeoxynucleotides to nuclear factor-kappaB inhibit reverse passive Arthus reaction in rat. Naunyn Schmiedebergs Arch Pharmacol 2001, 364:422-9.
  83. Ialenti A, Ianaro A, Maffia P, Carnuccio R, D'Acquisto F, Maiello FM, Di Rosa M: Role of nuclear factor-kappaB in a rat model of vascular injury. Naunyn Schmiedebergs Arch Pharmacol 2001, 364:343-50.
  84. D'Acquisto F, Maiuri MC, de Cristofaro F, Carnuccio R: Nitric oxide prevents inducible cyclooxygenase expression by inhibiting nuclear factor-kappa B and nuclear factor-interleukin-6 activation. Naunyn Schmiedebergs Arch Pharmacol 2001, 364:157-65.
  85. D'Acquisto F, de Cristofaro F, Maiuri MC, Tajana G, Carnuccio R: Protective role of nuclear factor kappa B against nitric oxide-induced apoptosis in J774 macrophages. Cell Death Differ 2001, 8:144-51.
  86. D'Acquisto F, Ialenti A, Ianaro A, Di Vaio R, Carnuccio R: Local administration of transcription factor decoy oligonucleotides to nuclear factor-kappaB prevents carrageenin-induced inflammation in rat hind paw. Gene Ther 2000, 7:1731-7.
  87. Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K, D'Acquisto F, Makuuchi M, Esumi H: Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2001, 276:2292-8.
  88. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S: Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-4.
  89. D'Acquisto F, Lanzotti V, Carnuccio R: Cyclolinteinone, a sesterterpene from sponge Cacospongia linteiformis, prevents inducible nitric oxide synthase and inducible cyclo-oxygenase protein expression by blocking nuclear factor-kappaB activation in J774 macrophages. Biochem J 2000, 346 Pt 3:793-8.
  90. D'Acquisto F, Ialenti A, Ianaro A, Carnuccio R: Nuclear factor-kappaB activation mediates inducible nitric oxide synthase expression in carrageenin-induced rat pleurisy. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:670-5.
  91. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, Addeo R, Makuuchi M, Esumi H: Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000, 95:189-97.
  92. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M: Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000, 292:156-63.
  93. Iuvone T, Den Bossche RV, D'Acquisto F, Carnuccio R, Herman AG: Evidence that mast cell degranulation, histamine and tumour necrosis factor alpha release occur in LPS-induced plasma leakage in rat skin. Br J Pharmacol 1999, 128:700-4.
  94. D'Acquisto F, Ianaro A, Ialenti A, Iuvone T, Colantuoni V, Carnuccio R: Activation of nuclear transcription factor kappaB in rat carrageenin-induced pleurisy. Eur J Pharmacol 1999, 369:233-6.
  95. D'Acquisto F, Ialenti A, Iuvone T, Di Rosa M, Carnuccio R: Inhibition of nuclear factor-kappaB prevents the loss of vascular tone in lipopolysaccharide-treated rats. Eur J Pharmacol 1999, 365:253-7.
  96. D'Acquisto F, Sautebin L, Iuvone T, Di Rosa M, Carnuccio R: Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappaB activation in J774 macrophages. FEBS Lett 1998, 440:76-80.
  97. Iuvone T, D'Acquisto F, Van Osselaer N, Di Rosa M, Carnuccio R, Herman AG: Evidence that inducible nitric oxide synthase is involved in LPS-induced plasma leakage in rat skin through the activation of nuclear factor-kappaB. Br J Pharmacol 1998, 123:1325-30.
  98. D'Acquisto F, Cicatiello L, Iuvone T, Ialenti A, Ianaro A, Esumi H, Weisz A, Carnuccio R: Inhibition of inducible nitric oxide synthase gene expression by glucocorticoid-induced protein(s) in lipopolysaccharide-stimulated J774 cells. Eur J Pharmacol 1997, 339:87-95.
  99. D'Acquisto F, Iuvone T, Rombola L, Sautebin L, Di Rosa M, Carnuccio R: Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett 1997, 418:175-8.
  100. Carotenuto A, Fattorusso E, Lanzotti V, Magno S, De Feo V, Carnuccio R, D'Acquisto F: Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum. J Nat Prod 1997, 60:1003-7.
  101. Iuvone T, Van Osselaer N, D'Acquisto F, Carnuccio R, Herman AG: Differential effect of L-NAME and S-methyl-isothiourea on leukocyte emigration in carrageenin-soaked sponge implants in rat. Br J Pharmacol 1997, 121:1637-44.
  102. Cicala C, Bucci M, F DA, Parente L, Cirino G: Sequential release of TNFalpha and phospholipase A(2) in a rat model of LPS-induced pleurisy. Mediators Inflamm 1997, 6:211-5.
  103. Sautebin L, Carnuccio R, D'Acquisto F, Rosa MD: Modulation of macrophage activation by prostaglandins. Mediators Inflamm 1996, 5:14-7.
  104. Iuvone T, D'Acquisto F, Carnuccio R, Di Rosa M: Nitric oxide inhibits LPS-induced tumor necrosis factor synthesis in vitro and in vivo. Life Sci 1996, 59:PL207-11.
  105. D'Acquisto F, Carnuccio R, d'Ischia M, Misuraca G: 5,6-Dihydroxyindole-2-carboxylic acid, a diffusible melanin precursor, is a potent stimulator of lipopolysaccharide-induced production of nitric oxide by J774 macrophages. Life Sci 1995, 57:PL401-6.
  106. Iuvone T, Capasso A, D'Acquisto F, Carnuccio R: Opioids inhibit the induction of nitric oxide synthase in J774 macrophages. Biochem Biophys Res Commun 1995, 212:975-80.

 

Prodotti della ricerca

Italiano:
Autore o co-autore di 113 pubblicazioni scientifiche peer-reviewed, oltre il 60% delle quali in qualità di primo o ultimo autore, per un totale di 9.926 citazioni e un indice h di 46 (Scopus). Il profilo bibliometrico completo è consultabile tramite ORCID (0000-0002-4513-1608) e Scopus Author ID 6701351362.

English:
Author or co-author of 113 peer-reviewed scientific publications, over 60% as first or last author, with a total of 9,926 citations and an h-index of 46 (Scopus). Full bibliometric details are available via ORCID (0000-0002-4513-1608) and Scopus Author ID 6701351362.

Link interessanti

 
 
Ultimo aggiornamento: 30-04-2025
torna ai contenuti torna all'inizio